<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        12-887-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TRANDATE TAB 200 MG.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LABETALOL HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        63.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ASPEN Bad Oldesloe GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ASPEN Bad Oldesloe GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASPEN PHARMA TRADING LIMITED (APTL)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C07AG01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1. What Trandate is and what it is used for</strong><br />Trandate contains the active substance labetalol. It is used to treat mild, moderate or severe hypertension (high blood pressure), hypertension in pregnancy (pregnancy-induced high blood pressure) and high blood pressure associated with angina pectoris (chest pain).</p><p>Labetalol (Trandate) belongs to a group of medicines called alpha- and beta-blocking agents. These medicines lower blood pressure by blocking receptors in the cardiovascular (circulatory) system, causing a decrease in blood pressure in the blood vessels far from the heart.</p><p>Please be aware that your doctor may have prescribed this medicine for another use and/or at another dosage than stated in the leaflet. Always follow the doctor&rsquo;s instructions that are stated on the pharmacy label on the bottle.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2. What you need to know before you take Trandate</strong></p><p><strong>Do not take Trandate</strong><br />- if you have a certain heart diseases (for example; second or third degree heart block unless you have a pacemaker, uncompensated heart failure)<br />- if you have ongoing low blood pressure<br />- if you have an extremely slow heart rate (severe bradycardia)<br />- If you have a condition known as Prinzmetal angina<br />- if you have asthma or a similar lung disease (obstructive airway disease)<br />- if you are allergic to labetalol or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before you take Trandate:<br />- if you have reduced liver function or liver damage<br />- if you have reduced kidney function<br />- if you have vascular disease , for example Raynauds syndrome, intermittent claudication.<br />- if you have diabetes mellitus (type 1 or type 2)<br />- if you have an overactive thyroid (thyrotoxicosis, hyperthyroidism)<br />- if you have previously had a severe allergic reaction (anaphylaxis) to any substance<br />- if you have heart failure or other problems with your heart (for example; poor left ventricular systolic function, first-degree atrio-ventricular block)<br />- if you know you are scheduled to have an operation - if you have metabolic acidosis (when your body produces too much acid, or when the kidneys are not removing enough acid from your body)<br />- if you have phaeochromocytoma (a particular type of tumour of the adrenal gland)<br />- if you have a condition called ischaemic heart disease</p><p>If you develop a low heart rate (bradycardia) as a result of taking Trandate, your doctor may lower your dose.</p><p>If you develop skin rashes and/or dry eyes or any kind of allergic reaction when you are taking Trandate, contact your doctor as they may reduce or discontinue your treatment. Always follow your doctor&rsquo;s instructions.</p><p>Do not stop taking Trandate suddenly, particularly if you have heart disease (ischaemic heart disease or angina pectoris). Talk to your doctor if you think you should stop taking Trandate.</p><p><strong>Surgery</strong><br />If you are having surgery requiring general anaesthetic, you must tell your surgeon ahead of your surgery that you are taking Trandate.</p><p>Labetalol can affect your pupils during cataract surgery. Tell your eye surgeon ahead of your surgery that you are using this medication. Do not stop taking labetalol before surgery unless your surgeon tells you to.</p><p><strong>Other medicines and Trandate</strong><br />Tell your doctor if you are taking, have recently taken or might take any other medicines before you are given Trandate. This is especially important for the following medicines:</p><p>- NSAIDs (non-steroidal anti-inflammatory drugs), for example; sulindac or indomethacin ,which are used to treat pain and inflammation<br />- digoxin (heart medication)<br />- adrenaline, which may be used to treat serious anaphylactic (allergic) reactions<br />- medicines for heart disorders (Class I antiarrhythmic agents e.g. disopyramide and quinidine) and (Class II antiarrhythmic agents e.g. amiodarone)<br />- other medicines that lower blood pressure (calcium blockers such as verapamil)<br />- tricyclic anti-depressants e.g. imipramine (used for the treatment of depression)<br />- cimetidine, which may be used for the treatment of ulcers and heartburn<br />- oral antidiabetics, for example; biguanides (e.g., metformin), sulfonylureas (e.g., glimepiride), meglitinides (e.g., repaglinide), and &alpha;-glucosidase inhibitors (e.g., acarbose) which are used to lower glucose levels in the blood<br />- ergotamine derivates, for example; ergotamine, dihydroergotamine which are used to treat migraine<br />- cholinesterase inhibitors, for example; donepezil, galantamine, rivastigmine which are used for the treatment of mild cognitive impairment, Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease<br />- nitrates, antipsychotics (eg. phenothiazine derivatives, chlorpromazine) and other antipsychotics, antidepressants<br />- clonidine (used for the treatment high blood pressure</p><p><strong>Tests</strong></p><p>This medicine may interfere with certain medical/laboratory tests, possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this medicine.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or are planning to have a baby, ask your doctor for advice before taking Trandate. It is possible that the foetus may be affected, but Trandate can be used if necessary, during pregnancy.</p><p>Trandate is excreted in breast milk. Breast feeding is therefore not recommended. If you are breast-feeding, ask your doctor for advice before taking Trandate.</p><p>Nipple pain have been reported.</p><p><strong>Trandate contains lactose</strong><br />If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p><strong>Trandate contains sunset yellow</strong></p><p>Trandate tablets contain the colouring agent sunset yellow (E110) which may cause allergic reactions.</p><p><strong>Driving and using machines</strong></p><p>It is likely that Trandate does not affect the ability to drive a vehicle or use machinery. Some people may, however, occasionally experience dizziness and/or fatigue. You should be aware that this may impair your ability to react, and therefore you should exercise caution until you are familiar with your reactions to this medicine.</p><p>You are responsible for assessing whether you are in a position to drive a motor vehicle or perform work that requires increased attention. One of the factors that may affect your ability in these respects is the use of drugs because of their effects and / or side effects. A description of these effects and side effects can be found in other sections. Read all the information in this leaflet for guidance. Discuss with your doctor or pharmacist if you are unsure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3. How to take Trandate</strong><br />Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Trandate tablets should be taken with food.</p><p>The dose is determined by your doctor, who will adjust it individually for you. The usual starting dose is 100 mg two times daily. Typically, the doses up to 800 mg per day may control your blood pressure. Up to 2400 mg (divided into 3 or 4 doses) per day may be given.</p><p>If you are an older person or if you have reduced liver function, your doctor may prescribe a lower dose.</p><p><strong>If you take more Trandate than you should</strong></p><p>Symptoms of labetalol (Trandate) overdose include extreme dizziness when you move to an upright position (sitting or standing) and sometimes low heart rate which you will feel as a low pulse. (bradycardia)</p><p>Contact a doctor or hospital if you think you have taken too much of this medicine or if a child has accidently ingested the medicine. Bring the medicinal packages to the emergency unit.</p><p><strong>If you forget to take Trandate</strong></p><p>Do not take a double dose to make up for a missed dose. Contact your doctor or pharmacist if you are unsure.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4. Possible side effects</strong><br />Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If you develop any of the following side effects seek urgent medical advice:</strong></p><p><strong>Very rare: may affect up to 1 in 10,000 people</strong><br />- systemic lupus erythemateous which has symptoms including joint pain, fever, skin rash and tiredness<br />- inability to urinate at all even though you have a full bladder (a medical emergency)<br />- angioedema which may have symptoms including swollen lips, face and tongue which could result in difficulty in breathing</p><p><strong>Other side effects include:</strong></p><p><strong>Very common: may affect more than 1 in 10 people</strong><br />- antibodies which are not associated with a disease</p><p><strong>Common: may affect up to 1 in 10 people</strong><br />- congestive heart failure<br />- raised liver function tests. This is usually reversible on withdrawal of the medicinal product<br />- dizziness, headache and tingling sensation in the scalp which are normally temporary and occur during the first few weeks of treatment<br />- blurred vision<br />- difficulty passing urine<br />- dizziness if you move too quickly from a lying to a sitting position, or from a sitting to a standing position, due to low blood pressure (postural hypotension). More common at very high doses or if the initial dose is too high or doses are increased too rapidly. This is normally temporary and occurs during the first few weeks of treatment<br />- congestion in your nose which is normally temporary and occurs during the first few weeks of treatment<br />- nausea<br />- erectile dysfunction (impotence) and ejaculatory failure<br />- tiredness and lack of energy which are normally temporary and occur during the first few weeks of treatment<br />- allergic reactions (hypersensitivity) may also include rash (of varying severity), itching, shortness of breath and very rarely fever or rapid swelling of the skin.</p><p><strong>Uncommon: may affect up to 1 in 100 people</strong></p><p>- depressed mood which is normally temporary and occurs during the first few weeks of treatment<br />- tightening of the lower airways (bronchospasm)<br />- vomiting and pain in your abdomen, immediately below your ribs<br />- sweating which is normally temporary and occurs during the first few weeks of treatment<br />- muscle cramps</p><p><strong>Rare: may affect up to 1 in 1,000 people</strong><br />- low heart rate which may be felt as a low pulse (bradycardia)</p><p><strong>Very rare: may affect up to 1 in 10,000 people</strong><br />- disruption of the electrical pulses that control the heart beat (heart block)<br />- inflammation of the liver (hepatitis) which is usually reversible on withdrawal of the medicinal product - hepatocellular jaundice (skin and the whites of the eyes turn yellow), cholestatic jaundice (symptoms include fatigue and nausea followed by pruritus, dark urine and jaundice and may include rash or fever) and hepatic necrosis (damaged liver tissue). These symptoms are usually reversible on withdrawal of the medicinal product<br />- worsening of the symptoms of Raynaud&rsquo;s Syndrome (cold fingers due to impaired blood circulation)<br />- swelling of your ankles. This is normally temporary and occurs during the first few weeks of treatment<br />- muscle inflammation and weakness caused by the medicine (toxic myopathy)<br />- tremor when Trandate is being used to treat high blood pressure associated with pregnancy<br />- eye irritation</p><p><strong>Not known frequency:</strong><br />- Nipple pain, Raynaud&#39;s phenomenon of the nipple (a phenomenon associated with less blood flow to the nipple).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5. How to store Trandate</strong><br />&bull; Keep this medicine out of the sight and reach of children.<br />&bull; Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. The expiry date refers to the last day of that month.<br />&bull; Store below 25&deg;C.<br />&bull; Do not use this medicine if you notice signs of deterioration.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Trandate contains</strong><br />- The active substance is labetalol hydrochloride. One tablet contains 100 mg or 200 mg of labetalol hydrochloride<br />- The other ingredients are, tablet core: lactose anhydrous, magnesium stearate, microcrystalline cellulose. Film coating: Opadry Orange 02A230001 (dye containing sodium benzoate, hypromellose, titanium dioxide and sunset yellow).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Trandate looks like and contents of the pack
Trandate 100 mg tablets are orange, round, biconvex, film-coated tablets engraved with TT01 on one side
Trandate 200 mg tablets are orange, round, biconvex, film-coated tablets engraved with TT02 on one side

Contents of the pack
100 mg film-coated tablets: Packs of 100 and 25 tablets in bottles.
200 mg film-coated tablets: Packs of 100 and 25 tablets in bottles.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p><strong>Marketing Authorisation Holder:</strong><br />Aspen Pharma Trading Limited<br />3016 Lake Drive<br />Citywest Business Campus<br />Dublin 24, Ireland</p><p><strong>Manufacturer:</strong><br />Aspen Bad Oldesloe GmbH,<br />Industriestrasse 32-36,<br />D-23843 Bad Oldesloe, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in {March/2022}, Version number {3}.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>1. ما هو تراندات وما هي دواع ي استخدامه</strong><br />يحتوي تراندات على المادة الفعالة لابيتالول، وهي مادة تستخدم في علاج ارتفاع ضغط الدم الطفيف، أو المتوسط أو الحاد (ضغط الدم المرتفع)، وارتفاع ضغط الدم خلال الحمل (ضغط الدم المرتفع الناتج عن الحمل) وارتفاع ضغط الدم المرتبط بالذبحة الصدرية (ألم الصدر) .</p><p>تنتمي مادة لابيتالول (تراندات) إلى مجموعة من الأدوية تُدعى حاصرات ألفا وبيتا. تقوم هذه المنتجات الدوائية بخفض ضغط الدم عن طريق حصر مستقبلات الجهاز القلبي الوعائي (الجهاز الدور ي)، مما يؤدي إلى خفض ضغط الدم في الأوعية الدموية البعيدة عن القلب .</p><p>يُرجى ملاحظة أنه من المحتمل أن طبيبك قد وصف لك هذا الدواء لاستخدام آخر و/أو جرعة مختلفة عن تلك الموصوفة في نشرة العبوة. اتبع دائما تعليمات الطبيب الموضحة على ملصق الزجاجة من الصيدلية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>2. ما الذي تحتاج لمعرفته قبل تناول تراندا ت</strong></p><p><strong>لا تتناول تراندات</strong><br />- إذا كنت مصابا بأمراض قلبية محددة(مثل انسداد القلب من الدرجة الثانية والثالثة، عدا في حالة وجود الناظمة القلبية الاصطناعية، أو فشل قلبي غير معالج).<br />- إذا كان ضغط الدم لديك منخفض باستمرار.<br />- إذا كانت ضربات القلب لديك متباطئة للغاية (بطء القلب الحاد)<br />- إذا كنت مصابا بحالة تُدعى ذبحة برنزميتال<br />- إذا كنت مصابا بمرض الربو أو مرض رئوي مشابه (مرض انسدادي رئوي) .<br />- إذا كنت مصابا بحساسية من مادة لابيتالول أو أي من المكونات الأخرى لهذا الدواء(مدرجة في القسم 6) .</p><p><strong>التحذيرات والاحتياطات</strong></p><p>تحدث إلى طبيبك أو الصيدلي قبل تناول تراندا ت :<br />- إذا كنت مصابا بقصور كبدي أو تلف كبدي .<br />- إذا كنت مصابا بقصور كلوي .<br />- إذا كنت مصابا بمرض وعائي، مثل متلازمة رينود، العرج المتقطع<br />- إذا كنت مصابا بداء السكري (النوع الأول أو الثاني).<br />- إذا كنت مصابا بفرط نشاط الغدة الدرقية (التسمم الدرقي، فرط الدرقية).<br />- إذا حدث لك من قبل رد فعل تحسسي خطير (اتقاء)من إحدى المواد.<br />- إذا كنت مصابا بفشل قلبي أو مشكلات قلبية أخرى (مثل قصور الوظيفة الانقباضية في البطين الأيسر أو إحصار أذيني بطيني من الدرجة ا لأولى).<br />- إذا كنت تعرف أنه من المقرر أن تخضع لجراحة .<br />- إذا كنت مصابا بالحماض الأيضي(عندما ينتج الجسم أحماضا بكمية أكبر من اللازم أو عندما لا تطرح الكلى الأحماض بكمية كافية من الجسم).<br />- إذا كنت مصابا بورم القواتم (نوع من الأورام يصيب الغدة الكظرية) .<br />- إذا كنت مصابا بحالة تدعى داء قلبي إقفاري.</p><p>إذا تعرضت لتباطؤ ضربات القلب (بطء القلب)نتيجة لاستخدام تراندات، يمكن للطبيب تقليل الجرعة التي تتناولها.</p><p>إذا أصبت بطفح جلدي و/أو جفاف العيون أو أي نوع من رد الفعل التحسسي عند تناول تراندات، فينبغي عليك الاتصال بالطبيب/الطبيبة الذي يمكنه/يمكنها حينها خفض الجرعة التي تتناولها أو إيقاف العلاج. اتبع دائما تعليمات الطبيب .</p><p>لا تنقطع عن تناول تراندات بشكل مفاجئ، على الأخص إذا كنت مصابا بمرض قلبي(داء قلبي إقفاري أو ذبجة صدرية). تحدث إلى طبيبك إذا كنت تعتقد أنه يجب عليك إيقاف العلاج بتراندات.</p><p><strong>الجراحة</strong></p><p>إذا كان من المقرر أن تخضع للجراحة تحت تخدير كلي، يجب أن تخبر الجراح أنك تستخدم تراندات قبل الجراحة .</p><p>فمن الممكن أن تؤثر مادة اللابيتالول على حدقتي العينين أثناء جراحة إعتام عدسة العين. أخبر الجراح أنك تتناول هذا المنتج الدوائي قبل الجراحة. يجب ألا تنقطع عن تناول لابيتالول قبل الجراحة، إلا إذا أخبرك الجراح بذلك .</p><p><strong>الأدوية الأخرى وتراندات</strong><br />أخبر طبيبك إن كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى، قبل البدء بتناول تراندات. فهذا مهم بشكل خاص للمنتجات الدوا ئية التالية :</p><p>- مضادات الالتهاب اللاستيرويدية(NSAID) مثل سلينداك أو إندوميثاسين والتي تستخدم كمسكن للآلام أو مضاد للالتهابات<br />- الديجوكسين (دواء للقلب)<br />- الأدرينالين، يُستخدم في علاج التأق الشديد (ردود الفعل التحسسية)<br />- منتجات دوائية لعلاج الأمراض القلبية (مضادات اضطراب النظم من الفئة الأولى مثل ديسوبيراميد وكوينيداين)و(مضادات اضطراب النظم من الفئة الثانية مثل أميودارون)<br />- منتجات دوائية أخرى لخفض ضغط الدم (حاصرات الكاليسيوم، مثل فيراباميل)<br />- مضادات الاكتئاب ثلاثية الحلقات، مثل إميبرامين (يستخدم في علاج الاكتئاب)<br />- سيميتدين الذي يمكن استخدامه في علاج قرحة المعدة و الحموضة<br />- مضادات السكري التي تؤخذ عن طريق الفم، مثل مجموعة البيغوانيد (مثل ميتفورمين)، السلفونيل يوريا (مثل جليميبرايد)، ومجموعة ميجليتنايدز (مثل ريباجلينيد)، ومثبطات الجلوكوسيديز ألفا (مثل أكاربوز) التي تُستخدم في خفض مستوى سكر الدم<br />- مشتقات الإرجوتامين، مثل إرجوتامين أو ثنائي هيدرات الإرجوتامين التي تستخدم في علاج الشقيقة<br />- مثبطات الكولينستيراز (مثل: دونيبيزيل، أو جالانتامين، أو ريفاستجمين)، التي تستخدم في علاج القصور&nbsp;&nbsp;الإدراكي الطفيف، ومرض ألزهايمر، ومرض باركنسون<br />-النترات، مضادات الذهان(مثل مشتقات فينوثيازين، كلوربرومازين)، ومضادات ذهان ومضادات اكتئاب أخرى&nbsp;<br />- كلونيدين، يُستخدم في علاج ارتفاع ضغط الدم .<br />&nbsp;</p><p><strong>الاختبارات</strong><br />يمكن للمنتج الدوائي أن يتفاعل مع اختبارات طبية/ معملية محددة و يمكن أن يتسبب في ظهورن تائج اختبارات خاطئة. تأكد أن جميع العاملين بالمعمل و أطباءك يعرفون أنك&nbsp;تتناول هذا الدواء .</p><p><strong>الحمل والرضاعة الطبيعية والخصوبة</strong><br />إذا كنت حاملاً أو تخططين للإنجاب، اطلبي من طبيبك المشورة قبل تناو ل تراندات. فمن الممكن أن يتأثر الجنين، إلا إنه يمكن استخدام تراندات في مرحلة الحمل&nbsp;عند اللزوم.</p><p>تراندات يفرز&nbsp;في حليب&nbsp;الثدي لذا لا يوصى بالرضاعة الطبيعية.إذا كنت ترضعين رضاعة طبيعية فيجب أن تستشيري&nbsp;طبيبك قبل تناول تراندات.</p><p>وردت بلاغات عن حدوث ألم في حلمات الثدي .</p><p><strong>يحتوي تراندات على اللاكتوز</strong></p><p>إذا أخبرك الطبيب أنك مصاب بعدم القدرة على تحمل بعض أنواع السكر، ا تصل بطبيبك قبل تناول هذا المنتج الدوائي.</p><p><strong>يحتوي تراندات على صفرة الغروب</strong></p><p>تحتوي أقراص تراندات على المادة الملونة صفرة الغروب(E110) التي قد تسبب ردود فعل تحسسية .</p><p><strong>القيادة واستخدام الآلات</strong><br />على الأرجح لن يؤثر تراندات على قدرتك على القيادة أو استخدام الآلات. إلا أن بعض الأشخاص أحيانا&nbsp;يشعرون بالدوار و/ أو الإجهاد.<br />يجب أن تعي&nbsp;حقيقة أن هذا قد يحد من قدرتك على التفاعل، و لذا يجب توخي الحذر إلى أن تعرف رد فعلك تجاه هذا الدواء .</p><p>أنت المعني بتقييم ما إذا كنت في وضع يمكنك من قيادة مركبة أو أداء عمل يتطلب المزيد من الانتباه. أحد العوامل التي قد تؤثر على قدرتك في هذا الصدد هو استخدام الأدوية بسبب تأثيراتها و/ أو آثارها الجانبية. يمكن العثور على وصف لهذه التأثيرات والآثار الجانبية في أقسام أخرى. اقرأ جميع المعلومات الواردة في هذه النشرة للحصول على إرشادات. ناقش مع طبيبك أو الصيدلي إذا كنت غير متأكد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>3. كيفية تناول تراندا ت</strong><br />تناول هذا الدواء دائما على النحو الذي يصفه لك الطبيب . استشر طبيبك أو الصيدلي إن لم تكن متأكداً.</p><p>يجب تناول أقراص تراندات مع الطعام.</p><p>سيحدد لك الطبيب الجرعة، وسيعدلها لك بما يناسبك. عادة ما تكون ا لجرعة الأولية 100 ملجم مرتين يوميا عادة يمكن للجرعات حتى 800 ملجم يوميا أن تتحكم في ضغط الدم.يمكن إعطاء حتى 2400 ملجم (مقسمة على 3 أو 4 جرعات) يوميا.</p><p>إذا كنت شخصا مسنا أو كنت مصابا بقصور كبدي، قد يصف لك الطبيب جرعة أقل .</p><p><strong>في حالة تناولت جرعة أكبر من اللازم من تراندات</strong><br />أعراض الجرعة المفرطة من لابيتالول (تراندات) تتضمن الدوار الشديد عند محاولة النهوض(إلى وضعية الوقوف أو الجلوس)، وفي بعض الأحيان تباطؤ ضربات القلب الذي ستشعر به كنبض بطيء (بطء القلب) .</p><p>اتصل بالطبيب أو إذا كنت تظن أنك تناولت جرعة أكبر من اللازم من الدواء، أو تناوله طفل عن طريق الخطا. قم بأخذ عبوات الدواء إلى المستشفى/عيادة الطوارئ .</p><p><strong>إذا نسيت تناول تراندات</strong><br />لا تتناول جرعة مضاعفة لتعويض الجرعة الفائتة . استشر طبيبك أو الصيدلي إن لم تكن متأكداً.</p><p>إن كان لديك أي استفسارات أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>4 . الآثار الجانبية المحتملة</strong><br />مثل جميع الأدوية، يمكن أن يتسبب هذا الدواء بظهور آثار جانبية، رغم أنه ليس بالضرورة أن يعاني منها الجميع.</p><p><strong>أطلب المشورة الطبية العاجلة إذا لاحظت ظهور أي من الآثار الجانبية التالية:</strong></p><p><strong>نادرة جدًا: قد تؤثر على 1 من 10000 شخص</strong><br />- الذئبة الحمامية الجهازية ، والتي قد تسبب أعراضا مثل آلام المفاصل، حمى، طفح جلدي، وإعياء<br />- عدم القدرة على التبول رغم امتلاء المثانة (حالة طبية طارئة&nbsp;)<br />- الوذمة الوعائية، والتي قد تتسبب في ظهور أعراض مثلت ورم الشفتين، والوجه واللسان وينتج عنها صعوبات تنفس</p><p><strong>من الآثار الجانبية الأخرى :</strong></p><p><strong>شائعة جداً: قد تؤثر على أكثر من 1 من كل 10 أشخاص</strong><br />- أجسام مضادة غير مرتبطة بالمرض</p><p><strong>شائعة: قد تؤثر على 1 من كل 10 أشخاص</strong><br />- فشل القلب الاحتقاني<br />- ارتفاع نتائج اختبارات وظائف الكبد والتي عادة ما تزول عند التوقف عن استخدام المنتج الدوائي<br />- الدوار، والصداع و شعور بالوخز في فروة الرأس، والذي عادة ما يكون مؤقتا،ً ويحدث خلال الأسابيع الأولى من العلاج<br />- تشوش الرؤية<br />- صعوبة التبول<br />- الدوار إذا نهضت فجأة من وضعية الاستلقاء إلى الجلوس أو من الجلوس إلى الوقوف بسبب انخفاض ضغط الدم (هبوط ضغط الدم الانتصابي) و تكون أكثر شيوعا مع ا لجرعات المرتفعة جداً أو إذا كانت الجرعة الأولية مرتفعة جداً أو تم زيادة الجرعات بشكل سريع جداً . عادة ما تكون هذه الآثار مؤقته إذ تحد ث خلال الأسابيع القليلة الأولى من العلاج<br />- احتقان الأنف ، عادة يكون مؤقتا إذ يحدث خلال الأسابيع القليلة الأولى من العلاج<br />- غثيان<br />- ضعف الانتصاب (ضعف جنسي) وفشل القذف<br />- الإجهاد أو انخفاض الطاقة، عادة ما يكون مؤقتا&nbsp; إذ يحدث خلال&nbsp;لأسابيع القليلة الأولى من العلاج<br />- تفاعلات تحسسية(فرط حساسية) قد تتضمن أيضا الطفح الجلدي (بدرجات متفاوتة)، والحكة، وصعوبة في التنفس، وقد يحدث في بعض الحالات النادرة للغاية حمى، أو تورم سريع في الجلد .</p><p><strong>غير شائعة: قد تؤثر على 1 من كل 100 شخص</strong><br />- شعور بالاكتئاب عادة ما يكون مؤقتا إذ يحدث خلال الأسابيع القليلة الأولى من العلاج<br />- تضيق المسالك التنفسية السفلية (تشنج قصبي)<br />- قيء وألم بالمعدة تحت الأضلع مباشرة<br />- تعرق و الذي عادة ما يكون مؤقتا إذ يحدث خلال الأسابيع القليلة الأولى من العلاج.<br />- تشنجات عضلية</p><p><strong>نادر ة: قد تؤثر على 1 من كل 1000 شخص</strong><br />- تباطؤ ضربات القلب، والذي يمكن الشعور به كنبض بطيء (بطء القلب)</p><p><strong>نادرة جد اً: قد تؤثر على 1 من كل 10000 شخص</strong><br />- اضطرابات في النبضات الكهربائية التي تتحكم في نبضات القلب (انسداد القلب).<br />- التهاب الكبد(التهاب كبدي)، والذي عادة ما يزول عند إيقاف العلاج بتراندات.<br />- يرقان خلوي كبدي (اصفرار الجلد وبياض العينين)، يرقان ركود الصفراء (تتضمن الأعراض الشعور بالتعب والغثيان، متبوعة بحكة، ولون داكن للبول ويرقان، وقد يتضمن أيضا طفحا جلديا أو حمى)، والنخر الكبدي (تضرر نسيج الكبد). عادة ما تزول هذه الأعراض عند إيقاف العلاج بالمنتج الدوائي<br />- تفاقم أعراض مرض رينود (برودة الأصابع بسبب مشاكل في الدورة الدموية)<br />- تورم الكاحلين. عادة ما يكون هذا التأثير مؤقت إذ يحدث خلال الأسابيع الأولى من العلاج.<br />- التهاب وضعف العضلات ناتج عن استخدام المنتج الدوائي(اعتلال عضلي تسممي)<br />- ارتجاف عند استخدام تراندات لعلاج ارتفاع ضغط الدم المرتبط بالحمل<br />- تهيج العينين</p><p><strong>معدل الحدوث غير معروف</strong><br />- ألم في حلمات الثدي، ظاهرة رينو في حلمات الثدي (ظاهرة مرتبطة بانخفاض تدفق الدم إلى الحلمات) .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>5. كيفية تخزين تراندات</strong><br />&bull; يُحفظ بعيداً عن مرأى ومتناول الأطفال .<br />&bull; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على العبوة و الزجاجة بعد EXP . يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر .<br />&bull; يحفظ في درجة حرارة أقل من 25 درجة مئوية .<br />&bull; لا تستخدم هذا الدواء إذا لاحظت أي من علامات التلف .<br />&bull; لا تتخلص من الأدوية الغير مستخدمة عن طريق مياه الصرف أو التفايات المنزلية. أسأل الصيدلي عن كيفية التخلص من الأدوية الغير مستخدمة. ستساعد هذه الإجراءات على الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>محتويات تراندات</strong><br />- المادة الفعالة هي لابيتالول هيدروكلوريد . يحتوي قرص واحد على 100 ملجم أو 200 ملجم من لابيتالول هيدروكلوريد<br />- المكونات الأخرى، القرص :لاكتوز لامائي، ستيارات مغنيسيوم، سيليولوز دقيق التبلور. الغلاف: أوبادري برتقالي 02A230001 (صبغة تحتوي على بنزوات الصوديم، هيبروميلوز، ثاني أكسيد التيتانيوم ، صفرة الغروب).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيف يبدو تراندات ومحتويات العبوة</strong></p><p>أقراص تراندات 100 ملجم المغلفة : أقراص برتقالية، مستديرة محدبة من الجانبين، ومغلفة، محفور على إحدى جانبيها TT01 .<br />أقراص تراندات 200 ملجم المغلفة : أقراص برتقالية، مستديرة محدبة من الجانبين، ومغلفة، محفور على إحدى جانبيها TT02 .</p><p><strong>محتويات العبوة</strong><br />أقراص 100 ملجم مغلفة: عبوات من 100 قرصا و 25 قرصا في زجاجات .<br />أقراص 200 ملجم مغلفة: عبوات من 100 قرصا و 25 قرصا في زجاجات .</p><p>قد لا تكون جميع أحجام العبوات مسوقة .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك حق التسويق والمصنع</strong></p><p><strong>مالك حق التسويق</strong><br />أسبن فارما تريدينغ المحدودة،<br />3016 ليك درايف، مجمع سيتي ويست<br />للأعمال، دبلن 24 أيرلندا</p><p><strong>الشركة المصنعة</strong><br />أسبن باد أولدسلو المحدودة المنطقة<br />الصناعية 32 - 36 ،<br />دي- 23843 باد أولدسلو، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في{مارس/ 2022}، رقم النسخة {3}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trandate Tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Labetalol hydrochloride 100 mg and 200 mg.

Excipients:
100 mg: Each film-coated tablet contains 14.625 mg lactose, anhydrous.
200 mg: Each film-coated tablet contains 29.25 mg lactose, anhydrous.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets 

Trandate 100 mg tablets are orange, round, biconvex, film-coated tablets engraved with TT01 on one side. 

Trandate 200 mg tablets are orange, round, biconvex, film-coated tablets engraved with TT02 on one side

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Mild, moderate or severe hypertension</li><li>&nbsp; Hypertensions in pregnancy</li><li>&nbsp; Angina pectoris with coexisting hypertension</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>Populations<strong>&nbsp;</strong></p><p><strong>Adults:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Indication</strong></p></td><td><p><strong>Dose</strong></p></td></tr><tr><td><p><strong>Mild, Moderate or Severe Hypertension</strong></p></td><td><p>Treatment should start with 100 mg twice daily. If necessary, increases in dosage of 100 mg twice daily should be made at intervals (2 to 14 days).&nbsp; Many patients&#39; blood pressure is controlled by 200 mg twice daily and up to 800 mg daily may be given as a twice daily regimen. In severe, refractory hypertension daily doses up to 2400 mg (in 3 or 4 divided doses) have been given. Hospital in-patients with severe hypertension may have daily increases in dosage.</p><p>Additive hypotensive effects may be expected if labetalol tablets are administered together with other hypotensives, e.g. diuretics, methyldopa etc. When transferring patients from such agents, the previous therapy should be gradually decreased.</p><p>For long-term control of hypertension following the use of labetalol injection, oral therapy with labetalol tablets should start at 100 mg twice daily.</p></td></tr><tr><td><p><strong>Hypertensions in Pregnancy</strong></p><p><strong>&nbsp;</strong></p></td><td><p>The initial dosage of 100 mg twice daily may be increased, if necessary, at weekly intervals, by 100 mg twice daily. The severity of the hypertension may require a three times daily regimen.</p><p>A total daily dose of 2400 mg should not be exceeded.</p><p>&nbsp;</p></td></tr><tr><td><p><strong>Angina Pectoris with Co-existing Hypertension</strong></p></td><td><p>The dose of labetalol is that required to control the hypertension.</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><strong>Paediatric population:</strong></p><p>The safety and efficacy of labetalol in paediatric patients aged 0 to 18 years have not been established. No data are available.</p><p><strong>Older people:</strong></p><p><em>In markets where a 50&nbsp;mg tablet is available:</em></p><p>For initiation of anti-hypertensive therapy, the usual starting dose is 100&nbsp;mg orally twice daily.&nbsp; However, an initial dosage of 50&nbsp;mg twice daily may be given.</p><p><em>In markets where a 50&nbsp;mg tablet is not available:</em></p><p>For initiation of anti-hypertensive therapy, the usual starting dose is 100&nbsp;mg orally twice daily.</p><p>Satisfactory blood pressure control may be achieved with lower maintenance doses than those required by younger patients.</p><p><strong>Patients with hepatic impairment</strong></p><p>In patients with hepatic impairment, lower doses of the oral formulation may be required (see Section 4.4 Special warnings and precautions for use).</p><p><strong><u>Method of Administration:</u></strong></p><p>Labetalol tablets should be taken with food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Non-selective beta-blockers should not be used in patients with asthma or a history of obstructive airway disease.
•	Labetalol injection and tablets are contraindicated in second or third degree heart block (unless pacemaker is in situ), cardiogenic shock and other conditions associated with severe and prolonged hypotension or severe bradycardia.
•	Uncompensated heart failure
•	Unstable/uncontrolled heart insufficiency
•	Sick sinus syndrome (including sinus atrial block) unless pacemaker in situ
•	Prinzmetal angina
•	Sinus node dysfunction
•	Labetalol injection and tablets are contraindicated for patients known to have hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Liver disease</strong></p><p>Care should be taken in liver disease. There have been very rare reports of severe hepatocellular injury with labetalol therapy.&nbsp; The hepatic injury is usually reversible and has occurred after both short and long term treatment.&nbsp; However, hepatic necrosis, in some cases with fatal outcome, has been reported. Appropriate laboratory testing should be done at the first sign or symptom of liver dysfunction. If there is laboratory evidence of liver injury or the patient is jaundiced, labetalol therapy should be stopped and not re-started.</p><p>Particular care should be taken when labetalol is used in patients with hepatic impairment as these patients metabolise labetalol more slowly than patients without hepatic impairment. Lower doses may be required (see Section 4.2 Posology and method of administration and 5.2 Pharmacokinetic properties; Special patient populations).</p><p><strong>Renal impairment</strong></p><p>Caution is advised when labetalol is used in patients with severe renal impairment GFR = 15-29 ml/min/1.73m<sup>2</sup>.</p><p><strong>Peripheral vascular disease </strong></p><p>Labetalol should be used with caution in patients with peripheral vascular disease as their symptoms may be exacerbated. Caution is advised in patients with peripheral arteriolarydisease (Raynauds syndrome, claudicatio intermittens) as labetalol may exacerbate their symptoms. Alpha-block may counter the unfortunate effect of beta-blockers.</p><p><strong>Symptomatic bradycardia</strong></p><p>If the patient develops symptomatic bradycardia, then the dosage of labetalol should be reduced.</p><p><strong>First-degree atrio ventricular block</strong></p><p>Given the negative effect of beta-adrenoceptor blocking medicinal products on atrioventricular conduction time, labetalol should be administered with caution to patients with first-degree atrio-ventricular block.</p><p><strong>Diabetes mellitus</strong></p><p>Care should be taken in case of uncontrolled or difficult-to-control diabetes mellitus&nbsp; As with other beta-adrenoceptor blocking medicinal products, labetalol may mask the symptoms of hypoglycaemia (tachycardia and tremor) &nbsp;in diabetic patients. The hypoglycaemic effect of insulin and oral hypoglycaemic agents may be enhanced by beta blockers.</p><p><strong>Thyrotoxicosis</strong></p><p>Beta blockers may mask the symptoms of <em>thyrotoxicosis</em>, but the thyroid function is not altered.</p><p><strong>Hypersensitivity to beta blockers</strong></p><p>Risk of anaphylactic reaction: While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.&nbsp; Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.</p><p><strong>Adrenaline</strong></p><p>If patients receiving labetalol require adrenaline treatment, a reduced dosage of adrenaline should be used as concomitant administration of labetalol with adrenaline may result in bradycardia and hypertension (see Section 4.5 Interaction with other medicinal products and other forms of interaction).</p><p>Upon severe influence of adrenaline as in pheochromocytoma, labetalol may cause a paradoxical</p><p>blood pressure elevation.</p><p><strong>Skin rashes and/or dry eyes</strong></p><p>There have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenoceptor blocking medicinal products.&nbsp; The reported incidence is small and in most cases the symptoms have cleared when the treatment was withdrawn.&nbsp; Gradual discontinuance of the medicinal product should be considered if any such reaction is not otherwise explicable.</p><p><strong>Intraoperative Floppy Iris Syndrome</strong></p><p>The occurrence of Intraoperative Floppy Iris Syndrome (IFIS, a variation of Small Pupil Syndrome) has been observed during cataract surgery in some patients on, or previously treated with, tamsulosin.&nbsp; Isolated reports have also been received with other alpha-1 blockers and the possibility of a class effect cannot be excluded. As IFIS may lead to increased procedural complications during the cataract operation, current or past use of alpha-1 blockers should be made known to the ophthalmic surgeon in advance of surgery.</p><p><strong>Heart failure or poor left ventricular function</strong></p><p>Special care should be taken with patients who suffer from heart failure or poor left ventricular systolic function.&nbsp; Labetalol is contraindicated in uncontrolled heart failure, but may be used with caution in patients who are well managed and free of symptoms. Heart failure should be controlled with appropriate therapy before use of labetalol.</p><p>Use of beta blockers implies a risk of inducing or exacerbating heart failure or obstructive lung disease. In case of heart failure the myocardial contractility should be maintained and the failure should be compensated. Patients with reduced contractility, particularly the elderly, should be monitored regularly for development of heart failure.</p><p>It is strongly recommended not to stop treatment with Trandate abruptly especially in patients with heart failure and patients with angina pectoris (risk of exacerbation of angina, myocardial infarction and ventricular fibrillation).</p><p><strong>Inhalation anaesthetics</strong></p><p>Care should be taken with concomitant treatment with inhalation anaesthetics (see section 4.5 Interaction with other medicinal products and other forms of interaction) Labetalol need not be discontinued prior to anaesthesia but patients should receive I.V. atropine prior to induction. Labetalol may enhance the hypotensive effects of volatile anaesthetics.</p><p><strong>Metabolic acidosis and pheochromocytoma</strong></p><p>Care should be taken in cases of metabolic acidosis and pheochromocytoma. In patients with pheochromocytoma, labetalol may be administered only after adequate alpha-blockade is achieved.</p><p><strong>Calcium antagonists</strong></p><p>Care should be taken if labetalol is used concomitantly with calcium antagonists, particularly the &quot;calcium entry blockers&quot;, which influence contractility and AV conduction negatively.</p><p>Care should be taken with concomitant administration of adrenaline, verapamil or class-1 antiarrhythmics (see Section 4.5 Interaction with other medicinal products and other forms of interaction).</p><p>Beta blockers have negative inotropic effect, but does not affect the positive inotropic effect of digitalis.</p><p><strong>Ischaemic heart disease</strong></p><p>Patients, particularly those with ischaemic heart disease, should not interrupt/discontinue abruptly labetalol therapy. Discontinuation in patients with ischemic heart disease should be done gradually during a period of 7&ndash;10 days, if possible.</p><p><strong>Excipients warnings; lactose and sunset yellow</strong></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>The medicinal product contains the colouring agent sunset yellow which can cause hypersensitivity reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The hypotensive effect of labetalol may be reduced when used in combination with prostaglandin synthetase inhibitors (NSAIDs).&nbsp; Dosage adjustments may therefore be necessary. Additive synergism may occur with other antihypertensive agents.</p><p>Labetalol fluoresces in alkaline solution at an excitation wavelength of 334 nanometres and a fluorescence wavelength of 412 nanometres and may therefore interfere with the assays of certain fluorescent substances including catecholamines.</p><p>The presence of labetalol metabolites in the urine may result in falsely elevated levels or urinary catecholamines, metanephrine, normetanephrine, and vaillylmandelic acid (VMA) when measured by fluorimetric or photometric methods.&nbsp; In screening patients suspected of having a pheochromocytoma and being treated with labetalol hydrochloride, a specific method, such as a high performance liquid chromatographic assay with solid phase extraction should be employed in determining levels of catecholamines.&nbsp;</p><p>Labetalol has been shown to reduce the uptake of radioisotopes of metaiodobenzylguanidine (MIBG).&nbsp; Care should therefore be taken in interpreting results from MIBG scintigraphy.</p><p>Concomitant administration of labetalol with adrenaline may result in bradycardia and hypertension (see Section 4.4 Special warnings and precautions for use).</p><p>Care should be taken if labetalol is used concomitantly with either Class I antiarrhythmic agents or calcium antagonists of the verapamil type.</p><p>Increased risk of myocardial depression in combination with class I antiarrhythmics (e.g. disopyramide and quinidine) and amiodarone (class II antiarrhythmics).</p><p>Risk of marked bradycardia and hypotension in combination with calcium antagonists with negative inotropic effect (e.g. verapamil, diltiazem).&nbsp; Especially in patients with impaired ventricular function and/or conduction disorders. In case of change from a calcium antagonist to a beta blocker or reverse, new intravenous therapy must not be initiated before at least 48 hours after withdrawal of the former treatment.</p><p>Concomitant treatment with calcium antagonists which are dihydropyridine derivates (e.g. nifedipine), may increase the risk of hypotension and may lead to heart failure in patients with latent cardial insufficiency. Digitalis glycosides in combination with beta blockers may increase the arioventricular conduction time. Labetalol may enhance digoxin&#39;s effect of reducing ventricular rate.</p><p>Beta blockers, especially non-selective beta blockers, may increase the risk of hypoglycemia in diabetic patients and mask the symptoms of hypoglycemia such as tachycardia and tremor, and delay the normalisation of blood sugar after insulin-induced hypoglycemia, especially non-selective beta blockers. Dose adjustments of oral antidiabetics and insulin may be necessary.</p><p>Care should be taken at general anaesthesia of patients using beta blockers. Beta blockers reduce the risk of arrhythmias during anaesthesia, but may lead to reduction of the reflectoric tachycardia and increase the risk of hypotension during anaesthesia. As anaesthetic, an agent with as low as possible degree of negative inotropic effect should be used. Heart function must be closely monitored and bradycardia due to vagal dominance should be corrected with intravenous administration of atropine, 1-2 mg intravenously (withdrawal prior to surgery, se section 4.2 Posology and method of administration).</p><p>For withdrawal in patients using both beta blockers and clonidine, gradual discontinuation of the beta blocker must be done several days before discontinuation of clonidine. This is to reduce the potential rebound hypertensive crisis which is a consequence of withdrawal of clonidine. Accordingly, when changing from clonidine to a beta blocker it is important to discontinue clonidine gradually, and start treatment with the beta blocker several days after clonidine has been withdrawn.</p><p>Concomitant treatment with cholinesterase inhibitors may increase the risk of bradycardia.</p><p>Concomitant treatment with alpha stimulating adrenergics may increase the risk of increased blood pressure (e.g. phenylpropanolamine and adrenaline), while concomitant treatment with beta stimulating adrenergics results in a mutual reduced effect (antidote effect).</p><p>Concomitant use of ergotamine derivates may increase the risk of vasospastic reactions in some patients.</p><p>Labetalol has been shown to increase the bioavailability of imipramine by more than 50% through the inhibition of its 2- hydroxylation. Labetalol in combination with imipramine may increase the effect of imipramine and concomitant use of tricyclic antidepressants. Concomitant use of tricyclic anti-depressants may increase the incidence of tremor.</p><p>Cimetidine may increase the bioavailability of labetalol and care is required in the oral dosing of the latter. Enhanced blood pressure reduction may occur in case of concomitant use of e.g. nitrates, antipsychotics (fentiazine derivates such as chloropromazine) and other antipsychotics, antidepressants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility</strong></p><p>There are no data on the effects of labetalol on fertility.</p><p><strong>Pregnancy</strong></p><p>Based on experience during human pregnancy, labetalol is not expected to increase the risk of congenital malformations. Animal studies do not indicate teratogenicity. However toxicity on embryo-foetal development has been noted (see Section 5.3). Due to the pharmacological action of alpha- and beta-adrenoceptor blockade, adverse effects on the foetus and neonate when used in the later stages of pregnancy (bradycardia, hypotension, respiratory depression, hypoglycaemia) should be borne in mind, as labetalol crosses the placental barrier. Close monitoring 24 - 48 hours after birth is required. &nbsp;Beta-blockers may reduce uterine blood flow.</p><p>Labetalol should only be used during pregnancy if the benefits to the mother outweigh the risk for the foetus.<strong>&nbsp;</strong></p><p><strong>Breast-feeding</strong></p><p>Labetalol is excreted in breast milk in small amounts (approximately 0.004 &ndash; 0.07 % of the maternal dose). No adverse effects have been reported so far. . Caution should be exercised when labetalol is administered to breast feeding women.</p><p>Labetalol is excreted in breast milk. Breast feeding is therefore not recommended.</p><ul><li>&nbsp;Nipple pain and Raynaud&#39;s phenomenon of the nipple have been reported (see section 4.8).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of labetalol is unlikely to result in any impairment of the ability of patients to drive or operate machinery.&nbsp; However, it should be taken into account that occasionally dizziness or fatigue may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p>Among the most common undesirable effects observed with labetalol tablets and collected from post-marketing reports include: congestive heart failure, postural hypotension,&nbsp; hypersensitivity, lichenoid rash, drug fever, raised liver function tests, difficulty in micturition, dizziness, headache, tingling sensation in scalp, blurred vision, nasal congestion, nausea, erectile dysfunction and ejaculatory failure.</p><p><strong>Tabulated list of adverse reactions</strong><br />The following convention has been utilised for the classification of frequency:<br />Very common &ge;1/10<br />Common &ge;1/100 and &lt;1/10<br />Uncommon &ge;1/1000 and &lt;1/100<br />Rare &ge;1/10,000 and &lt;1/1000<br />Very rare &lt;1/10,000</p><p>Side-effects indicated by a hash (#) are usually transient and occur during the first few weeks of treatment.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Body System</p></td><td><p>&nbsp;</p></td><td><p>Side effects</p></td></tr><tr><td rowspan="2"><p>Immune System Disorders</p></td><td><p>Very common</p></td><td><p>Positive anti-nuclear antibodies unassociated with disease</p></td></tr><tr><td><p>Common</p></td><td><p>Hypersensitivity, lichenoid rash, drug fever</p></td></tr><tr><td><p>Psychiatric Disorders</p></td><td><p>Uncommon</p></td><td><p>#Depressed mood</p></td></tr><tr><td rowspan="2"><p>Nervous System Disorders</p></td><td><p>Common</p></td><td><p>#Dizziness, #headache, #tingling sensation in scalp</p></td></tr><tr><td><p>Very rare</p></td><td><p>Tremor in the treatment of hypertension of pregnancy</p></td></tr><tr><td rowspan="2"><p>Eye Disorders</p></td><td><p>Common</p></td><td><p>Blurred vision</p></td></tr><tr><td><p>Very rare</p></td><td><p>Eye irritation</p></td></tr><tr><td rowspan="3"><p>Cardiac Disorders</p></td><td><p>Common</p></td><td><p>Congestive Heart Failure</p></td></tr><tr><td><p>Rare</p></td><td><p>Bradycardia</p></td></tr><tr><td><p>Very rare</p></td><td><p>Heart Block</p></td></tr><tr><td><p>Vascular Disorders</p></td><td><p>Common</p></td><td><p>#Postural hypotension</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Very rare</p></td><td><p>Exacerbation of the symptoms of Raynaud&rsquo;s Syndrome</p></td></tr><tr><td><p>Respiratory, Thoracic and Mediastinal Disorders</p></td><td><p>Common</p></td><td><p>#Nasal Congestion</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Uncommon</p></td><td><p>Bronchospasm</p></td></tr><tr><td rowspan="2"><p>Gastrointestinal Disorders</p></td><td><p>Common</p></td><td><p>Nausea</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Vomiting, epigastric pain</p></td></tr><tr><td rowspan="2"><p>Hepatobiliary Disorders</p></td><td><p>Common</p></td><td><p>Raised Liver Function Tests</p></td></tr><tr><td><p>Very rare</p></td><td><p>Hepatitis,&nbsp; hepatocellular jaundice, cholestatic jaundice, hepatic necrosis</p></td></tr><tr><td><p>Skin and Subcutaneous Tissue Disorders</p></td><td><p>Uncommon</p></td><td><p>#Sweating</p></td></tr><tr><td rowspan="2"><p>Musculoskeletal and Connective Tissue Disorders</p></td><td><p>Uncommon</p></td><td><p>Cramps</p></td></tr><tr><td><p>Very rare</p></td><td><p>Toxic myopathy, systemic lupus erythemateous</p></td></tr><tr><td rowspan="2"><p>Renal and Urinary Disorders</p></td><td><p>Common</p></td><td><p>Difficulty in micturition</p></td></tr><tr><td><p>Very rare</p></td><td><p>Acute retention of urine</p></td></tr><tr><td rowspan="2"><p>Reproductive System and Breast Disorders</p></td><td><p>Common</p></td><td><p>Erectile dysfunction, ejaculatory failure</p></td></tr><tr><td><p>Not known</p></td><td><p>Nipple pain, Raynaud&#39;s phenomenon of the nipple</p></td></tr><tr><td rowspan="2"><p>General Disorders and Administration Site Conditions</p></td><td><p>Common</p></td><td><p>#Tiredness, #lethargy</p></td></tr><tr><td><p>Very rare</p></td><td><p>#Ankle oedema</p></td></tr></tbody></table><p><strong>Description of selected adverse reactions:</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><u>Immune system disorders</u></p></td></tr><tr><td><p>Hypersensitivity reactions reported include rash (including reversible lichenoid rash), pruritus, dyspnoea and very rarely drug fever or angioedema.</p></td></tr><tr><td><p>&nbsp;</p><p><u>Vascular disorders</u></p></td></tr><tr><td><p>Postural hypotension is more common at very high doses or if the initial dose is too high or doses are increased too rapidly.</p></td></tr><tr><td><p>&nbsp;</p><p><u>Hepatobiliary disorders</u></p></td></tr><tr><td><p>The signs and symptoms of hepatobiliary disorders are usually reversible on withdrawal of the medicinal product.</p><p>&nbsp;</p></td></tr></tbody></table><p><strong><u>To reports any side effect(s):</u></strong></p><p><strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><ul><li>The National Pharmacovigilance Centre (NPC):&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul><p>- SFDA Call Center: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: https://ade.sfda.gov.sa/<strong>&nbsp; </strong></p></td></tr></tbody></table><p><strong>- Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>-&nbsp; Please contact the relevant competent authority.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and signs:</u></p><p>Profound cardiovascular effects are to be expected, e.g. excessive, posture-sensitive hypotension and sometimes bradycardia. Oliguric renal failure has been reported after massive overdosage of labetalol orally. In one case, the use of dopamine to increase the blood pressure may have aggravated the renal failure.</p><p><u>Treatment:</u></p><p>Patients should be laid supine with the legs raised.</p><p>Parenteral adrenergic/anticholinergic therapy should be administered as needed to improve circulation.</p><p>Haemodialysis removes less than 1% labetalol hydrochloride from the circulation.</p><p>Further management should be as clinically indicated or as recommended by the national poison centre, where available.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>Alpha and beta blockers<strong> <em>ATC code </em></strong>C07AG01</p><p><strong>Mechanism of action</strong></p><p>Labetalol lowers blood pressure by blocking peripheral arteriolar alpha-adrenoceptors, thus reducing peripheral resistance, and by concurrent beta-blockade, protects the heart from reflex sympathetic drive that would otherwise occur.</p><p><strong>Pharmacodynamic effects</strong></p><p>Cardiac output is not significantly reduced at rest or after moderate exercise.&nbsp; Increases in systolic blood pressure during exercise are reduced but corresponding changes in diastolic pressure are essentially normal.&nbsp; All these effects would be expected to benefit hypertensive patients. In patients with angina pectoris coexisting with hypertension, the reduced peripheral resistance decreases myocardial afterload and oxygen demand. All these effects would be expected to benefit hypertensive patients and those with coexisting angina.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pharmacokinetics </u></strong></p><p><strong><em>Absorption</em></strong></p><p>Labetalol chemically consists of four stereoisomers with different pharmacodynamics effect. Labetalol is rapidly absorbed from the gastrointestinal tract with peak plasma levels occurring 1 to 2 h after oral administration.&nbsp; There is a significant first-pass metabolism leading to a bioavailability of approximately 25 %, but there is considerable variation. The bioavailability of labetalol is increased in elderly subjects.</p><p><strong><em>Distribution</em></strong></p><p>About 50% of labetalol in the blood is protein bound. Only negligible amounts of labetalol cross the blood brain barrier in animal studies. Labetalol crosses the placental barrier and is secreted in breast milk.</p><p><strong><em>Biotransformation</em></strong></p><p>Labetalol is metabolised mainly through conjugation to inactive glucuronide metabolites.</p><p><strong><em>Elimination:</em></strong></p><p>The glucuronide metabolites are excreted both in the urine and via the bile, into the faeces. Less than 5% of the labetalol dose is excreted unchanged in urine and bile. &nbsp;The plasma half-life of labetalol is about 4 h.</p><p>Special Patient Populations<strong>&nbsp;</strong></p><p><strong>Hepatic Impairment</strong></p><p>Labetalol undergoes significant but variable first-pass metabolism when given by the oral route. In a study of 10 patients with histologically proven cirrhosis, exposure to oral labetalol was increased approximately three-fold compared with healthy controls. Inter-subject variability in both patients and controls was high (approximately 2.5-fold). Patients with hepatic impairment may require lower oral doses of labetalol (see Section 4.2 Posology and method of administration and Section 4.4 Special warnings and precautions for use).</p><p>Clinical Studies<em>&nbsp;</em></p><p><em>No text.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogensis, mutagenesis and teratogenesis</strong></p><p>There was no evidence of mutagenic potential from <em>in vitro</em> and <em>in vivo</em> tests.</p><p>Labetalol showed no evidence of carcinogenicity in long-term studies performed in mice and rats.</p><p>No teratogenicity was observed in rats and rabbits at oral doses 6 and 4 times the maximum recommended human dose, respectively. Increased foetal resorptions were seen in both species at doses approximating the maximum recommended human dose. A teratology study performed with labetalol in rabbits at intravenous doses up to 1.7 times the maximum recommended human dose revealed no evidence of drug-related harm to the foetus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Tablet core:</strong><br />Lactose anhydrous<br />Magnesium stearate<br />Microcrystalline cellulose</p><p><strong>Film coating:</strong><br />Hypromellose<br />Sodium benzoate<br />Titanium dioxide<br />Sunset Yellow</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                100 mg/100Tablet: 3 years 

200 mg/100Tablet: 3 years

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet container (plastic).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen Pharma Trading Limited
3016 Lake Drive
Citywest Business Campus
Dublin 24
Ireland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>